Cargando…
Addressing unmet needs in the treatment of COPD
The burden of chronic obstructive pulmonary disease (COPD) is considerable, both socially and economically. Central to COPD management is the use of long-acting bronchodilators, which provide patients with optimal bronchodilation and improvements in symptoms. The once-daily, long-acting β(2)-agonist...
Autores principales: | Patalano, Francesco, Banerji, Donald, D’Andrea, Peter, Fogel, Robert, Altman, Pablo, Colthorpe, Paul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487321/ https://www.ncbi.nlm.nih.gov/pubmed/25176969 http://dx.doi.org/10.1183/09059180.00004014 |
Ejemplares similares
-
Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis
por: Vogelmeier, Claus, et al.
Publicado: (2016) -
Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study
por: Wedzicha, Jadwiga A, et al.
Publicado: (2017) -
Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study
por: Anzueto, Antonio R., et al.
Publicado: (2018) -
LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis
por: Rodrigo, Gustavo J, et al.
Publicado: (2017) -
An Innovative Approach to Designing Digital Health Solutions Addressing the Unmet Needs of Obese Patients in Europe
por: Patalano, Roberta, et al.
Publicado: (2021)